Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yin, You"'
Autor:
Richard G. Langley, Yin You, Andrew Blauvelt, Yaung-Kaung Shen, Kim A. Papp, Tsen-Fang Tsai, Megan Miller, Ya-Wen Yang, Luis Puig
Publikováno v:
Journal of the American Academy of Dermatology. 86:827-834
Guselkumab effectively treats moderate-to-severe psoriasis.To evaluate the cumulative safety experience of guselkumab using pooled data from the VOYAGE 1 and 2 studies through 5 years.Patients were randomized to guselkumab, placebo with crossover to
Autor:
Jerry Bagel, Carle Paul, Kurt Gebauer, Diamant Thaçi, Yin You, Susan Flavin, April W. Armstrong, Lyn Guenther, Andrew Blauvelt, Richard G. Langley, Kristian Reich, Bruce Randazzo, Ming-Chun Hsu
Publikováno v:
Journal of Dermatological Treatment. 33:2317-2324
Purpose Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe plaque psoriasis. Materials and methods ECLIPSE, was a Phase 3, multicenter, 56-week, double-blinded, active-comparator study of guselkumab vs. secukinumab (I
Autor:
Yaung-Kaung Shen, Peter Foley, Megan Miller, Kristian Reich, Kenneth B. Gordon, Yin You, Michael Song, April W. Armstrong, Chenglong Han
Publikováno v:
American Journal of Clinical Dermatology. 21:881-890
Guselkumab effectively treats moderate-to-severe psoriasis. Results of continuous guselkumab treatment through 4 years from VOYAGE 2 are presented. At baseline, 992 patients were randomized to receive guselkumab 100 mg every 8 weeks, placebo, or adal
Autor:
Kenneth B. Gordon, Y. W. Yang, Chenglong Han, Peter Foley, Bruce Strober, Yaung-Kaung Shen, Cem Griffiths, April W. Armstrong, Megan Miller, Yin You, Kristian Reich
Publikováno v:
The British journal of dermatologyReferences. 185(6)
BACKGROUND: Psoriasis is a chronic disease requiring long-term therapy. OBJECTIVES: Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. METHODS: In total, 1829 patients were randomized at baseline to rec
Autor:
Jeffrey J. Crowley, Kenneth B. Gordon, Shu Li, Michael Song, Kristian Reich, Chenglong Han, Yin You, Steven Fakharzadeh
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 4:147-152
Background: Patient-reported and clinician-determined outcomes do not always correlate in clinical trials for psoriasis, even among those with clear skin. Objective: To compare clinical responses with patient-reported outcomes among patients with pso
Autor:
Michael Song, Peter Foley, April W. Armstrong, Chenglong Han, Yin You, Yaung-Kaung Shen, Kim A. Papp, Kristian Reich
Publikováno v:
American Journal of Clinical Dermatology
Background Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis. Objectives Our objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs
Autor:
Jashin J. Wu, Yin You, Melinda Gooderham, Francisco A. Kerdel, Luis Puig, Yaung-Kaung Shen, Bruce Randazzo
Publikováno v:
JOURNAL OF DERMATOLOGICAL TREATMENT
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Altres ajuts: Janssen Research and Development (JRD) Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c0d92dd42fede3e4f3fc37a5eecff9f
https://ddd.uab.cat/record/269696
https://ddd.uab.cat/record/269696
Autor:
Megan Miller, Yin You, Kim Papp, Michael Song, Yaung-Kaung Shen, Cem Griffiths, Andrew Blauvelt
Publikováno v:
Annals of the Rheumatic Diseases. 80:1297-1298
Background:VOYAGE 1, a phase-3, double-blinded, placebo- and active comparator-controlled study evaluated the efficacy and safety of guselkumab (GUS; a fully human anti-interleukin-23 monoclonal antibody) in patients with moderate-to-severe plaque ps
Autor:
April W. Armstrong, Michael Song, Kristian Reich, Chenglong Han, Yin You, Y. Wasfi, Yaung-Kaung Shen, Peter Foley, Kenneth B. Gordon
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 32:1940-1949
BACKGROUND: Anxiety and depression are clinically significant comorbidities associated with psoriasis. Improvements in psoriasis are known to decrease anxiety and depression. Guselkumab, an anti-interleukin-23 monoclonal antibody, has demonstrated ef
Autor:
Megan Miller, Luis Puig, Bruce Strober, Diamant Thaçi, Yin You, Yaung-Kaung Shen, Melinda Gooderham, Ya-Wen Yang, Tsen-Fang Tsai, Andrew Blauvelt
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB154